Tonix Pharmaceut Stock Price, News & Analysis

Tonix Pharmaceuticals (Nasdaq: TNXP) reported its Q2 2021 financial results, highlighting ongoing clinical trials for TNX-1300 and TNX-1900, and a Phase 3 study for TNX-102 SL. The company aims to enhance R&D and manufacturing capabilities with new facilities and expects a cash balance of approximately $166 million as of June 30, 2021. Research and development expenses rose to $18.1 million, while the net loss was $23.6 million, or $0.07 per share. The company’s focus includes advancing COVID-19 product candidates and expanding its CNS pipeline.

Tonix Pharmaceuticals announced a groundbreaking ceremony for its new Advanced Development Center (ADC) in New Bedford, MA, scheduled for August 3, 2021. The 45,000 sq. ft. facility will enhance the company's capacity for vaccine development, focusing on infectious diseases, including COVID-19. It aims to be operational in the first half of 2022 and will employ up to 70 staff. The ADC will support clinical manufacturing under Good Manufacturing Practices (GMP) and is a significant step toward addressing public health challenges.

Tonix Pharmaceuticals (Nasdaq: TNXP) announced the acquisition of a 48,000 square foot R&D facility in Frederick, MD, from Southern Research. This facility will expand Tonix's capabilities in developing vaccines and antiviral drugs, specifically against COVID-19 and other infectious diseases. The acquisition aims to enhance the production and efficiency of Tonix’s vaccine candidates, including TNX-1800 and TNX-801. Expected to close by Q4 2021, this strategic move addresses challenges revealed by the COVID-19 pandemic and positions Tonix within Maryland’s biotech corridor.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced it will stop enrolling new participants in the Phase 3 RALLY study of TNX-102 SL (5.6 mg) for fibromyalgia management. This decision follows an interim analysis by the Independent Data Monitoring Committee (IDMC), indicating that the treatment is unlikely to show statistically significant improvements compared to placebo. The study initially enrolled 514 participants across 40 sites. Tonix plans to continue studying currently enrolled participants and expects to report topline results in Q4 2021.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced the appointment of Carolyn E. Taylor to its Board of Directors, effective July 16, 2021. Taylor brings over 35 years of corporate law experience, including 15 years as a partner at Covington & Burling LLP. CEO Seth Lederman expressed optimism about Taylor's broad transactional expertise contributing to the company's growth. Tonix focuses on developing treatments for CNS and immunology conditions, with key candidates including TNX-102 SL for fibromyalgia and TNX-1800 for COVID-19.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced its inclusion in the Russell 3000® and Russell 2000® indexes effective June 28, 2021. This addition reflects the company’s growth and achievements over the past year, as stated by CEO Seth Lederman. Russell indexes are crucial for investment managers, with about $10.6 trillion in assets benchmarked against them. Tonix focuses on developing CNS and immunology product candidates, with ongoing studies for fibromyalgia and vaccines targeting COVID-19 and smallpox.

Tonix Pharmaceuticals (Nasdaq: TNXP) plans to develop TNX-102 SL as a potential treatment for Long COVID, officially known as Post-Acute Sequelae of COVID-19 (PASC). Over 30% of COVID-19 patients develop chronic symptoms such as fatigue and brain fog. An FDA pre-IND meeting is scheduled for Q3 2021 to discuss the clinical development plan. TNX-102 SL is also in mid-Phase 3 for fibromyalgia, with results expected in Q3 2021 and Q1 2022. The drug aims to improve sleep quality, potentially addressing the core symptoms of Long COVID.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that CEO Seth Lederman will present at the Raymond James Human Health Innovation Conference on June 23, 2021, at 8:00 a.m. ET. Investors can arrange virtual meetings through the conference coordinator. A webcast of the presentation will be accessible on Tonix's website. The company is focused on developing small molecules and biologics for CNS and immunology conditions. Its lead candidate, TNX-102 SL, is in mid-Phase 3 for fibromyalgia, with interim data expected in Q3 2021.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that CEO Seth Lederman will participate in the BIO Digital Conference on June 10-11 and 14-18, 2021. The company's presentation will be available on demand for registered attendees. Tonix focuses on developing therapeutics for CNS and immunology, with lead candidates TNX-102 SL for fibromyalgia and TNX-1800 for COVID-19 vaccination. Interim results from their second Phase 3 study for TNX-102 SL are expected in Q3 2021.